These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15205347)

  • 1. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
    Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
    Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic adenoviral therapy in gallbladder carcinoma.
    Tekant Y; Davydova J; Ramirez PJ; Curiel DT; Vickers SM; Yamamoto M
    Surgery; 2005 May; 137(5):527-35. PubMed ID: 15855925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.
    Yamamoto M; Davydova J; Wang M; Siegal GP; Krasnykh V; Vickers SM; Curiel DT
    Gastroenterology; 2003 Oct; 125(4):1203-18. PubMed ID: 14517802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
    Kanerva A; Bauerschmitz GJ; Yamamoto M; Lam JT; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
    Gene Ther; 2004 Mar; 11(6):552-9. PubMed ID: 14999227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
    Hoffmann D; Meyer B; Wildner O
    J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
    Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
    J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
    Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
    Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
    Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
    Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment.
    Uchino J; Takayama K; Harada A; Kawakami Y; Inoue H; Curiel DT; Nakanishi Y
    Cancer Gene Ther; 2005 Sep; 12(9):737-48. PubMed ID: 15861179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer.
    Ono HA; Davydova JG; Adachi Y; Takayama K; Barker SD; Reynolds PN; Krasnykh VN; Kunisaki C; Shimada H; Curiel DT; Yamamoto M
    J Gastroenterol; 2005 Jan; 40(1):31-42. PubMed ID: 15692787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
    Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
    Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
    Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
    J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.
    Kanerva A; Mikheeva GV; Krasnykh V; Coolidge CJ; Lam JT; Mahasreshti PJ; Barker SD; Straughn M; Barnes MN; Alvarez RD; Hemminki A; Curiel DT
    Clin Cancer Res; 2002 Jan; 8(1):275-80. PubMed ID: 11801569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.